Latest From Ramsey Baghdadi
NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.
FDA medical review leaders have been remarkable on balancing the two challenges of finding treatments for COVID-19 and keeping everything else running on time.
White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.
Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.